Findings confirmed that patient-specific autologous dendritic cell vaccines (DCV) induced a different immune response associated with longer survival than autologous tumor cell vaccines (TCV)
IRVINE, Calif.--(BUSINESS WIRE)-- AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today the publication of a paper titled, Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial, in the Journal of Translational Medicine. Robert O. Dillman, M.D., chief medical officer at AIVITA, and Gabriel I Nistor, M.D., chief scientific officer at AIVITA, authored the article.
The publication provides insight into the innate and adaptive immune responses induced by patient-specific autologous dendritic cell vaccines (DCV) and autologous tumor cell vaccines (TCV), and their impact on survival. DCV was associated with a multipronged innate and adaptive immune response and correlated with improved survival compared to TCV.
In a randomized Phase 2 trial conducted in patients with melanoma, blood samples were obtained at one week before and one week after a course of three weekly injections, which either included dendritic cells loaded ex vivo with antigens from autologous irradiated tumor-initiating cells (DCV), or autologous irradiated tumor-initiating cells alone (TCV). Cytokine network analysis techniques used to analyze the serologic immune responses generated by each immunotherapy confirmed they triggered differing responses. The results help provide insight into a potential underlying immunologic mechanism of action that contributes to improved survival in DCV-treated patients.
This analysis reinforces conclusions from our patient-specific cancer vaccine survival data, which suggested that ex-vivo processing of the same tumor antigens by autologous dendritic cells induces a more advantageous immune response than antigen-only based tumor cell vaccines, said Dr. Nistor. This is reassuring as we continue to further optimize our unique approach in which we use enhanced autologous dendritic cells for targeting each patients own tumor.
AIVITA is currently conducting three independent clinical studies investigating its platform immunotherapy in patients with ovarian cancer, glioblastoma and melanoma. AIVITA uses 100% of proceeds from the sale of its ROOT of SKIN skincare line to support the development of its cancer therapeutic pipeline.
About AIVITAS Clinical Trials
OVARIAN CANCER
AIVITAs ovarian Phase 2 double-blind study is active and enrolling approximately 99 patients who are being randomized in a 2:1 ratio to receive either the autologous tumor-initiating cell-targeting immunotherapy or autologous monocytes as a comparator.
Patients eligible for randomization and treatment will be those (1) who have undergone debulking surgery, (2) for whom a cell line has been established, (3) who have undergone leukapheresis from which sufficient monocytes were obtained, (4) have an ECOG performance grade of 0 or 1 (Karnofsky score of 70-100%), and (5) who have completed primary therapy. The trial is not open to patients with recurrent ovarian cancer.
For additional information about AIVITAs AVOVA-1 trial patients can visit: http://www.clinicaltrials.gov/ct2/show/NCT02033616
GLIOBLASTOMA
AIVITAs glioblastoma Phase 2 single-arm study is active and is enrolling approximately 55 patients to receive the tumor-initiating cell-targeting immunotherapy.
Patients eligible for treatment will be those (1) who have recovered from surgery such that they are about to begin concurrent chemotherapy and radiation therapy (CT/RT), (2) for whom an autologous tumor cell line has been established, (3) have a Karnofsky Performance Status of > 70 and (4) have undergone successful leukapheresis from which peripheral blood mononuclear cells (PBMC) were obtained that can be used to generate dendritic cells (DC). The trial is not open to patients with recurrent glioblastoma.
For additional information about AIVITAs AV-GBM-1 trial please visit: http://www.clinicaltrials.gov/ct2/show/NCT03400917
MELANOMA
AIVITAs melanoma Phase 1B open-label, single-arm study will establish the safety of administering anti-PD1 monoclonal antibodies in combination with AIVITAs tumor-initiating cell-targeting immunotherapy in patients with measurable metastatic melanoma. The study will also track efficacy of the treatment for the estimated 14 to 20 patients. This trial is not yet open for enrollment.
Patients eligible for treatment will be those (1) for whom a cell line has been established, (2) who have undergone leukapheresis from which sufficient monocytes were obtained, (3) have an ECOG performance grade of 0 or 1 (Karnofsky score of 70-100%), (4) who have either never received treatment for metastatic melanoma or were previously treated with enzymatic inhibitors of the BRAF/MEK pathway because of BRAF600E/K mutations and (5) are about to initiate anti-PD1 monotherapy.
For additional information about AIVITAs AV-MEL-1 trial please visit: http://www.clinicaltrials.gov/ct2/show/NCT03743298
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITAs skin care products support the treatment of people with cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200423005260/en/
Read more here:
- Following Their Calling to Help Young Cancer Patients and Beyond - Stanford Children's Health - September 28th, 2024
- Greenberg Regenerative Medicine Celebrates Nearing 2 Years of Success with Pioneering VSEL Therapy - PR.com - September 28th, 2024
- Discovery clears hurdle in growing organs for transplants : Newsroom - UT Southwestern - September 26th, 2024
- Cell Therapy Market is Expected to Gain USD 60696.42 Million with a Growing CAGR of 19.20% by 2030 - openPR - September 25th, 2024
- Stem Cell Therapy Market To Reach USD 44 Billion By 2032 (Updated 2024) - Market.us Media - United States Market News - September 25th, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 23rd, 2024
- The new frontier of luxury travel is a $44,000 course of stem cells and a longevity club stocked with IV stations - Fortune - September 23rd, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 20th, 2024
- Exploring Regenerative Medicine and Its Impact on Modern Disease Management - Baltimore Post-Examiner - September 18th, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 16th, 2024
- Stem Cell Restore Review: Can It Boost Your Stem Cell Activity for Lasting Health? - Vashon-Maury Island Beachcomber - September 14th, 2024
- Stem Cell Therapy Market valued at USD 3.40 Billion by 2030 As Revealed In New Report - WhaTech - September 14th, 2024
- Stem Cell Manufacturing Market Projected to Witness Huge Growth by 2024-2031 As Revealed In New Report - WhaTech - September 14th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 12th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - StockTitan - September 10th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - Newswire - September 10th, 2024
- Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure - News-Medical.Net - September 8th, 2024
- Stem Cell Therapy Market Is Estimated To Reach $928.6 Million by 2031 | CAGR 16.2% - EIN News - September 8th, 2024
- USC researchers receive funding to develop next generation of intelligent biocomputers - EurekAlert - September 8th, 2024
- Risk Factors and Indications for Stem Cell Transplants in MDS - Targeted Oncology - September 6th, 2024
- Cell Therapy Market Size to Hit USD 28.98 Billion by 2032, - GlobeNewswire - September 6th, 2024
- Blood stem cells grown in the lab for the first time ever - Earth.com - September 6th, 2024
- Top 3 Grants in Regenerative Medicine: August 2024 - RegMedNet - September 6th, 2024
- New approach moves cell therapy closer to treating many disorders - Medical Xpress - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- What Sets Immunotherapy Regenerative Medicine Apart in a Crowded Regenerative Market? - Flaunt Magazine - September 2nd, 2024
- Tiny Test Tubes Sort Stem Cells for Improved Therapy - The Scientist - August 31st, 2024
- Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax - August 31st, 2024
- From stem cells to technology, the next Wisconsin RISE initiative focuses on improving health - University of Wisconsin-Madison - August 29th, 2024
- aHSCT Stem Cell Therapy for MS | National MS Society - National MS Society - August 29th, 2024
- Are Stem Cells the Secret to Anti-Aging? - The Edge - August 22nd, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Scientists discover method to activate dormant stem cells in the brain - Medical Xpress - August 20th, 2024
- New way to extend 'shelf life' of blood stem cells can improve gene therapy - Medical Xpress - August 20th, 2024
- Where Are the Cell Therapies for Type 1 Diabetes? - Inside Precision Medicine - August 14th, 2024
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire - August 14th, 2024
- Stem Cell Therapy Market to expand to a market value of USD 3.40 Billion by 2030, with a CAGR of 13.4 percentage - openPR - August 14th, 2024
- Stem cell therapy unveiled: Discover the truth and boost donor rates - IOL - August 12th, 2024
- Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace - August 10th, 2024
- T.J. Watt Reveals He Received Stem Cell Treatment On Knee This Offseason - Steelers Depot - August 10th, 2024
- Anti-aging enthusiasts are getting $16,500 injections to make their knees young again - Business Insider Nederland - August 10th, 2024
- Regenerative Medicine Market Exclusive Insights on Size, Share and Profit - WhaTech - August 8th, 2024
- Fresh Study Reveals the Mesenchymal Stem Cells Market Trends, Strategy and Overview - WhaTech - August 6th, 2024
- Allogeneic Stem Cell Transplantation Market Exclusive Survey Report with Detailed Analysis to 2031 By Top R... - WhaTech - August 6th, 2024
- Salk awarded $3.6 million by the California Institute for Regenerative Medicine to advance research on brain aging - Salk Institute - August 2nd, 2024
- Professor awarded grant to study stem cell therapy for inflammatory bowel disorders - Mercer University - August 2nd, 2024
- Stem cell therapy advances: MSCs show potential in managing COVID-19 and influenza infections - News-Medical.Net - July 31st, 2024
- Scientists aboard international space station perform stem cell research and biomanufacturing in microgravity - BioProcess Insider - July 31st, 2024
- UCLA receives $2 million to develop regenerative medicine therapies for spinal cord injury - UCLA Newsroom - July 31st, 2024
- The Phoenix of stem cells: pluripotent cells in adult tissues and peripheral blood - Frontiers - July 31st, 2024
- Regenerative Medicine Market to Reach USD 194.9 Billion by 2032 - Market.us Media - United States Market News - July 31st, 2024
- Stem Cell Exosome Therapeutic Market Business Insights, Key Trend Analysis - Economica - July 31st, 2024
- One of the 7 people cured of HIV tells his story. Can his cure work for others? - Michigan Public - July 31st, 2024
- Novel stem cell treatment for osteoarthritis reduces pain by 58% - NewsBytes - July 30th, 2024
- Stem Cell Manufacturing Market Size To Reach $21.8 Billion By 2028 As Revealed In New Report - WhaTech - July 30th, 2024
- PRP, stem cell therapyhelp in curing infertility - The Times of India - July 30th, 2024
- Australian researchers develop a donor stem cell therapy for the successful treatment of osteoarthritis - News Hub - July 28th, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 28th, 2024
- Enggartiasto Lauds Stem Cell Therapy at RSCM - Jakartaglobe.id - July 28th, 2024
- Investigating the effect of alemtuzumab in allogeneic hematopoietic cell transplantation - Medical Xpress - July 28th, 2024
- Does This 'Stem Cell' Therapy Contain Any Actual Stem Cells? - Medscape - July 22nd, 2024
- Stem Cells and Malignant Mesothelioma - Mesothelioma.net Blog - July 18th, 2024
- Selma Blair on Getting Back on Track With MS Treatment: People Dont Get How Expensive It Is to Be Disabled - Hollywood Reporter - July 18th, 2024
- Common therapies contain different cell types, study finds - News-Medical.Net - July 18th, 2024
- Stem Cell Therapy with Saffron Extract Promotes Uterine Healing - Natural Science News - July 18th, 2024
- Half-matched stem cell transplant on 11-yr-old boy - The Times of India - July 12th, 2024
- Efficacy and Safety of Stem Cell Therapy for Orthopedic Conditions, Including Osteoarthritis and Bone Defects - Cureus - July 8th, 2024
- Stem Cell Therapy Market Poised to Reach USD 52.1 Billion by 2034 at a 12.1% of CAGR - PharmiWeb.com - July 8th, 2024
- "Living Fillings" Could be the Future Thanks to Stem Cells - NewBeauty Magazine - July 8th, 2024
- R3 Stem Cell Wins 2024 Global Regenerative Medicine Company of the Year for Third Time - EIN News - July 8th, 2024
- NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025 - The Straits Times - July 8th, 2024
- Sorting therapeutic stem cells by function improves healing after heart attack, lab study shows - Medical Xpress - July 4th, 2024
- July: cruk-grant | News and features - University of Bristol - July 4th, 2024
- Stem cell therapy shows promise for hirschsprung disease - Open Access Government - June 30th, 2024
- Stem Cells & Other Injectable Treatments: Solution or Scam? Episode 3 of 'The Bone Whisperers' Podcast - NYU Langone Health - June 28th, 2024
- Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro ... - Nature.com - June 28th, 2024
- Advancing regenerative medicine therapies UCI News - UCI News - June 26th, 2024
- Stem cell therapy could be breakthrough against type 1 diabetes - Medical Xpress - June 26th, 2024
- Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research - University of Colorado Anschutz Medical Campus - June 26th, 2024
- Stem Cell Therapy Could Be Breakthrough Against Type 1 Diabetes - The Caledonian-Record - June 26th, 2024
Recent Comments